Should monitoring of fibroblast growth factor-23 levels in dialysis patients be a part of routine clinical practice?

Saab, Georges; Lam, Mildred; Navaneethan, Sankar D; Slatopolsky, Eduardo

Saab, Georges; Lam, Mildred; Navaneethan, Sankar D; Slatopolsky, Eduardo.

Affiliation

Saab G; MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio.

Semin Dial ; 27(6): 565-8, 2014.

Article in En | MEDLINE | ID: mdl-25040017

Subject(s)

Fibroblast Growth Factors/blood; Kidney Failure, Chronic/blood; Kidney Failure, Chronic/therapy; Renal Dialysis; Calcification, Physiologic/physiology; Fibroblast Growth Factor-23; Humans; Hypophosphatemia/blood; Hypophosphatemia/etiology; Kidney Failure, Chronic/complications

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Dialysis / Fibroblast Growth Factors / Kidney Failure, Chronic Type of study: Etiology_studies Limits: Humans Language: En Journal: Semin Dial Journal subject: NEFROLOGIA Year: 2014 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google